Dianthus Therapeutics (DNTH) Institutional Ownership

47.53% of Dianthus Therapeutics' stock is owned by institutional investors. Learn more on DNTH's institutional investor holdings.

Of the 145 institutional investors that purchased Dianthus Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vestal Point Capital LP ($2.81M), Wellington Management Group LLP ($2.58M), Braidwell LP ($2.11M), TCG Crossover Management LLC ($1.68M), State Street Corp ($1.25M), Marshall Wace LLP ($1.01M), and Polar Capital Holdings Plc ($1.00M).

Institutional investors have bought a total of 19,303,507 shares in the last 24 months. This purchase volume represents approximately $777.10M in transactions.

Of the 44 institutional investors that sold Dianthus Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Vestal Point Capital LP ($2.02M), RA Capital Management L.P. ($1.26M), Avidity Partners Management LP ($1.10M), Bain Capital Life Sciences Investors LLC ($779.76K), Tri Locum Partners LP ($476.86K), Octagon Capital Advisors LP ($470K), and Woodline Partners LP ($357.81K).

Institutional investors have sold a total of 8,164,476 shares in the last 24 months. This volume of shares sold represents approximately $378.20M in transactions.